NASDAQ:ENTX Entera Bio - ENTX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Entera Bio Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $1.05 -0.01 (-1.07%) (As of 03/24/2023 11:21 AM ET) Add Compare Share Share Today's Range$1.00▼$1.1050-Day Range$0.83▼$1.4452-Week Range$0.47▼$3.00Volume19,328 shsAverage Volume246,592 shsMarket Capitalization$30.20 millionP/E RatioN/ADividend YieldN/APrice Target$7.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Entera Bio MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside614.3% Upside$7.50 Price TargetShort InterestHealthy0.39% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.75Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.70 out of 5 starsMedical Sector815th out of 989 stocksBiological Products, Except Diagnostic Industry140th out of 166 stocks 3.5 Analyst's Opinion Consensus RatingEntera Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.50, Entera Bio has a forecasted upside of 614.3% from its current price of $1.05.Amount of Analyst CoverageEntera Bio has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.39% of the float of Entera Bio has been sold short.Short Interest Ratio / Days to CoverEntera Bio has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Entera Bio has recently increased by 181.49%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEntera Bio does not currently pay a dividend.Dividend GrowthEntera Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENTX. Previous Next 1.8 News and Social Media Coverage News SentimentEntera Bio has a news sentiment score of -0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Entera Bio this week, compared to 0 articles on an average week.Search Interest4 people have searched for ENTX on MarketBeat in the last 30 days. MarketBeat Follows9 people have added Entera Bio to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Entera Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.15% of the stock of Entera Bio is held by insiders.Percentage Held by InstitutionsOnly 20.12% of the stock of Entera Bio is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Entera Bio is -7.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entera Bio is -7.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEntera Bio has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Entera Bio (NASDAQ:ENTX) StockEntera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH, GLP-E, and hGh, The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.Read More Receive ENTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ENTX Stock News HeadlinesMarch 23, 2023 | finance.yahoo.comEntera Bio Regains Compliance with Nasdaq Listing RequirementsMarch 10, 2023 | finance.yahoo.comWill Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?March 24, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. February 20, 2023 | finance.yahoo.comEntera Bio (ENTX) to Report Q4 Earnings: What's in the Cards?February 15, 2023 | finance.yahoo.comEntera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal OsteoporosisFebruary 13, 2023 | finance.yahoo.comEntera Bio to Participate in the SVB Securities Global Biopharma ConferenceFebruary 10, 2023 | finance.yahoo.comEntera Bio Ltd. (ENTX) Outpaces Stock Market Gains: What You Should KnowFebruary 2, 2023 | finance.yahoo.comEntera Bio Ltd. (ENTX) Flat As Market Gains: What You Should KnowMarch 24, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …January 27, 2023 | finance.yahoo.comEntera Bio Ltd. (ENTX) Stock Sinks As Market Gains: What You Should KnowJanuary 25, 2023 | finance.yahoo.comEntera Bio Ltd. (ENTX) Flat As Market Sinks: What You Should KnowJanuary 19, 2023 | finance.yahoo.comEntera Bio Ltd. (ENTX) Gains As Market Dips: What You Should KnowJanuary 7, 2023 | finance.yahoo.comEntera Bio Ltd. (ENTX)January 4, 2023 | msn.comWhy Oblong Shares Are Trading Higher By 59%; Here Are 20 Stocks Moving PremarketNovember 23, 2022 | 247wallst.comCentillion Fund Inc. Ups Stake in Entera Bio (ENTX)November 11, 2022 | finanznachrichten.deEntera Bio Ltd.: Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022November 10, 2022 | finance.yahoo.comEntera Bio Ltd. (ENTX) Reports Q3 Loss, Misses Revenue EstimatesNovember 10, 2022 | finance.yahoo.comEntera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022October 6, 2022 | seekingalpha.comFDA agrees to single phase 3 trial by Entera for bone disorder drug EB613 to support approvalOctober 6, 2022 | nasdaq.comEntera Bio Inks Deal With FDA For Single Phase 3 Trial To Support NDA For EB613 For OsteoporosisOctober 6, 2022 | finance.yahoo.comEntera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of OsteoporosisOctober 1, 2022 | finance.yahoo.comIs Entera Bio (NASDAQ:ENTX) In A Good Position To Invest In Growth?September 21, 2022 | finance.yahoo.comEntera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613’s Potential Impact on Wednesday, September 28th @ 10am ETSeptember 17, 2022 | seekingalpha.comENTX Entera Bio Ltd.September 12, 2022 | finance.yahoo.comEntera Bio to Present at H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 12, 2022 | finance.yahoo.comEntera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual MeetingAugust 11, 2022 | finance.yahoo.comEntera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ENTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ENTX Company Calendar Last Earnings11/11/2021Today3/24/2023Next Earnings (Estimated)3/28/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ENTX CUSIPN/A CIK1638097 Webwww.enterabio.com Phone(722) 532-7151FaxN/AEmployees18Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.50 High Stock Price Forecast$10.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+614.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,190,000.00 Net Margins-1,796.49% Pretax Margin-4,901.05% Return on Equity-27.72% Return on Assets-24.70% Debt Debt-to-Equity RatioN/A Current Ratio12.73 Quick Ratio12.73 Sales & Book Value Annual Sales$570,000.00 Price / Sales53.05 Cash FlowN/A Price / Cash FlowN/A Book Value$0.95 per share Price / Book1.11Miscellaneous Outstanding Shares28,800,000Free Float27,321,000Market Cap$30.24 million OptionableNot Optionable Beta1.79 Key ExecutivesMiranda J. ToledanoChief Executive Officer & DirectorHillel GalitzerChief Operating OfficerDana Yaacov GarbeliChief Financial OfficerArthur C. SantoraChief Medical OfficerIrena Ben-YakarInternal AuditorKey CompetitorsEvaxion Biotech A/SNASDAQ:EVAXCardiol TherapeuticsNASDAQ:CRDLIN8bioNASDAQ:INABSolid BiosciencesNASDAQ:SLDBMiromatrix MedicalNASDAQ:MIROView All CompetitorsInsiders & InstitutionsMillennium Management LLCBought 35,968 shares on 2/15/2023Ownership: 0.160%RA Capital Management L.P.Sold 1,786,406 shares on 2/14/2023Ownership: 1.028%Renaissance Technologies LLCBought 118,300 shares on 2/13/2023Ownership: 0.485%Sean EllisBought 30,000 shares on 11/11/2022Total: $15,900.00 ($0.53/share)Miranda Jayne ToledanoBought 50,000 shares on 11/11/2022Total: $26,500.00 ($0.53/share)View All Insider TransactionsView All Institutional Transactions ENTX Stock - Frequently Asked Questions Should I buy or sell Entera Bio stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Entera Bio in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ENTX shares. View ENTX analyst ratings or view top-rated stocks. What is Entera Bio's stock price forecast for 2023? 2 equities research analysts have issued 1 year target prices for Entera Bio's shares. Their ENTX share price forecasts range from $5.00 to $10.00. On average, they anticipate the company's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 614.3% from the stock's current price. View analysts price targets for ENTX or view top-rated stocks among Wall Street analysts. How have ENTX shares performed in 2023? Entera Bio's stock was trading at $0.73 at the beginning of the year. Since then, ENTX stock has increased by 43.8% and is now trading at $1.05. View the best growth stocks for 2023 here. Are investors shorting Entera Bio? Entera Bio saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 86,700 shares, an increase of 181.5% from the February 13th total of 30,800 shares. Based on an average daily volume of 219,900 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.4% of the shares of the company are sold short. View Entera Bio's Short Interest. When is Entera Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023. View our ENTX earnings forecast. How were Entera Bio's earnings last quarter? Entera Bio Ltd. (NASDAQ:ENTX) released its quarterly earnings results on Thursday, November, 11th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.03. The firm had revenue of $0.14 million for the quarter. Entera Bio had a negative trailing twelve-month return on equity of 27.72% and a negative net margin of 1,796.49%. What other stocks do shareholders of Entera Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Entera Bio investors own include Fulcrum Therapeutics (FULC), Cara Therapeutics (CARA), Gilead Sciences (GILD), Supernus Pharmaceuticals (SUPN), VIVUS (VVUS), Vaxart (VXRT), AbbVie (ABBV), Acasti Pharma (ACST) and Allena Pharmaceuticals (ALNA). When did Entera Bio IPO? (ENTX) raised $11 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 1,400,000 shares at $8.00 per share. Maxim Group served as the underwriter for the IPO and Joseph Gunnar was co-manager. What is Entera Bio's stock symbol? Entera Bio trades on the NASDAQ under the ticker symbol "ENTX." Who are Entera Bio's major shareholders? Entera Bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (1.03%), Renaissance Technologies LLC (0.48%) and Millennium Management LLC (0.16%). Insiders that own company stock include Miranda Jayne Toledano, Ramesh Ratan, Ron Mayron, Sean Ellis and Yonatan Malca. View institutional ownership trends. How do I buy shares of Entera Bio? Shares of ENTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Entera Bio's stock price today? One share of ENTX stock can currently be purchased for approximately $1.05. How much money does Entera Bio make? Entera Bio (NASDAQ:ENTX) has a market capitalization of $30.24 million and generates $570,000.00 in revenue each year. The company earns $-12,190,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis. How can I contact Entera Bio? Entera Bio's mailing address is FIFTH FLOOR KIRYAT HADASSAH MINRAV BUILDING, JERUSALEM L3, 9112002. The official website for the company is www.enterabio.com. The company can be reached via phone at (722) 532-7151 or via email at investorrelations@enterabio.com. This page (NASDAQ:ENTX) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.